Vital Signs - Embryonic Stem Cells: High Potential and Controversy


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on December 1, 2008, provides an strategic overview of trends and issues surrounding embryonic stem cell development in the U.S. Additionally, a company spotlight is provided for Seattle Genetics, a biotechnology company focused on the development and commercialization of therapeutic monoclonal antibodies for the treatment of autoimmune diseases and cancer. Reimbursement and regulatory news from the FDA is also provided for the week of November 17, 2008.

Table of Contents

Vital Signs - Embryonic Stem Cells: High Potential and ControversyVital Signs: 1 December 2008This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.